Site icon TechArena

Egypt’s InCurA Raises an Undisclosed Amount in a pre-Seed Round

IncurA

IncurA

Egypt’s healthtech startup, InCurA, has raised an undisclosed amount in a pre-seed round led by regional investors including Tiye Angels, Kaust Innovation Ventures (KIV), UI Investments, Pharos Holding, and AUC Angels. The startup was founded in 2021 by Wessam Sarhan and Moussa Salem. It specializes in the manufacture of medical products aimed at bleeding control.

The funding will be used to advance InCurA’s mission of improving access to healthcare and to power its expansion.

This funding round marks Tiye Angels’, Egypt angel investment network, inaugural investment. It demonstrates Tiye Angels’ commitment to Gender Lens Investing (GLI), highlights the potential of female founders in Egypt, and demonstrates investor confidence in Incura’s potential to drive positive impact.

Tiye Angels was launched in December 2019 and receives support from USAID’s Business Egypt Program to fund female entrepreneurs.

What they Said:

“We are thrilled to announce our first investment in InCurA,” said Christine Sedky, Tiye Angels Network Manager. “The company has a talented team, holds intellectual property rights for its products, has established licensing and manufacturing partnerships, and has a clear vision for addressing a critical need in the medical devices market. We are confident in InCurA’s potential growth and the positive impact it will have on the Egyptian and regional economies.”

InCurA, founded by Wessam Sarhan (CEO and co-founder) and Moussa Salem ElSayed (CTO and co-founder), is the first IP factory in MENA dedicated to creating high-quality medical devices that provide innovative solutions with scalable manufacturing capabilities. InCurA’s two leading products are hemostatic agents (used to limit bleeding during dental or surgical procedures) that have enhanced efficacy compared to existing products globally.  ColiSorB, a hemostatic sponge, and CurASeal, a hemostatic powder, both exhibit enhanced hemostatic efficacy, accelerated clotting, and lower blood loss. InCurA’s solutions not only improve on current market offerings but also serve as strong import-replacement products for the region, where over 90% of medical devices are imported.

“Tiye Angels’ investment is more than just capital,” CEO and founder Wesam Sarhan of Incura said. “We are grateful for the alignment with our values and support of Tiye Angels and look forward to working with them to democratize access to healthcare and accelerate the expansion of InCurA.”

Read: Moove Secures $100 Million in Funding at a valuation of $750m

Exit mobile version